Ruxolitinib for Chronic Graft-versus-Host Disease
- 21 October 2021
- journal article
- letter
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 385 (17), 1631-1632
- https://doi.org/10.1056/nejmc2113499
Abstract
To the Editor: Zeiser et al. (July 15 issue)1 report a significantly better overall response in patients treated with ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease (GVHD), as they did 1 year ago for acute GVHD.2 The authors conclude that ruxolitinib was superior to control therapy, with no new safety signals. The data fail to convince. The authors describe chronic GVHD as “a leading cause…of nonrelapse-associated death.” However, overall survival did not differ substantially between the groups after half a year of treatment, with no fewer deaths from GVHD in the ruxolitinib group. Furthermore, the primary end point of overall response . . .Keywords
This publication has 7 references indexed in Scilit:
- Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host DiseaseThe New England Journal of Medicine, 2021
- Cost-effectiveness of defibrotide for treatment of severe veno-occlusive disease: it is time for evidence based economic evaluationsJournal of Medical Economics, 2021
- Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host DiseaseThe New England Journal of Medicine, 2020
- Reliability and Validity of the Modified 7-Day Lee Chronic Graft-versus-Host Disease Symptom ScaleTransplantation and Cellular Therapy, 2019
- Association of Socioeconomic Status with Chronic Graft-versus-Host Disease OutcomesTransplantation and Cellular Therapy, 2017
- Patient socioeconomic status as a prognostic factor for allo-SCTBone Marrow Transplantation, 2008
- Socioeconomic Inequalities in Health in 22 European CountriesThe New England Journal of Medicine, 2008